The #CureVac case should make vaccine sceptics sceptical about their scepticism. It's mRNA technology, it's been heaviley propped up by the government - but unlike others, it hasn't delivered in its trial, so its chances of approval are close to zero now.https://t.co/x3Rhpp8rE7

— Andreas Backhaus (@AndreasShrugged) June 17, 2021

A reminder of how lucky we are to have 4-6 viable vaccines in use worldwide presently. Science is rarely that successful. https://t.co/vuAHy93OQO

— Dr. Ubaka Ogbogu (@UbakaOgbogu) June 17, 2021

CureVac社製ワクチンは第3相試験の中間結果で有効率47%と既出のワクチンと比較して最低値を出したと。
CureVac製はファイザーやモデルナと同じmRNAワクチンだが、通常の冷蔵庫で月単位の保存が可能であることもあり、低〜中所得国での普及に期待されていた。
https://t.co/1xjtw0j021

— Sukuna (@SukunaBikona7) June 17, 2021

https://t.co/rcue8NNfdi#German firm #CureVac said its #Covid19 #vaccines was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the #EuropeanUnion . #CCPVirus #TakeDownTheCCP

— LA_HimalayaAngel_club (@himalayaangel) June 17, 2021